Miltenyi Biotec, a global player in cell and gene therapy (CGT) solutions, has launched India’s first dedicated Cell and Gene Therapy Center of Excellence (CoE) in Hyderabad. This milestone reaffirms the company’s commitment to advancing biotechnology and fostering innovation in India’s fast-growing life sciences sector.
A State-of-the-Art Facility in Genome Valley
Located in Genome Valley, India’s premier life sciences hub, the Miltenyi Innovation and Technology Centre (MITC) spans 1,800 square meters.The center accelerates cell and gene therapy development by integrating expertise and best practices. It also leverages cutting-edge technologies to tackle critical diseases, including cancer.
Equipped for Innovation and Collaboration
MITC features a showroom displaying advanced MACS instruments and a CliniMACS Prodigy platform for therapy development and manufacturing.
As reported by biospectrumindia.com, the facility also provides interactive training opportunities and serves as a collaborative hub. It will host seminars and workshops on immunology, stem cell biology, and cancer research. These events will also cover other key areas in biomedical science.
Grand Inauguration with Industry Leaders
The center was inaugurated by Telangana’s Minister for Industries and IT, D. Sridhar Babu, alongside Dr. Kathrin Misera-Lang, Consul General (interim) of the Federal Republic of Germany to India, Chennai. They were joined by Dr. Toon Overstijns, Managing Director of Miltenyi Biomedicine, and other distinguished guests.
Government’s Vision for Biotechnology Growth
During the event, D. Sridhar Babu emphasized the significance of the facility, stating, “This center strengthens our healthcare ecosystem and supports Telangana’s vision of becoming a global leader in advanced biotechnology and healthcare solutions, particularly in cell and gene therapies.”
Driving Advancements in Biomedical Research
Dr. Boris Stoffel, Chief Commercial Officer and Board Member of Miltenyi Biotec B.V. & Co. KG, highlighted MITC’s impact, saying, “This facility will accelerate biomedical research and support the scientific and medical community in developing new therapies for diseases with limited treatment options. By collaborating closely with researchers, physicians, and industry partners, we aim to provide the necessary tools and expertise to deliver transformative therapies to patients.”